Clinical Trial

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction

Study acronym: BENEFIT-AMI
Recruiting
View on ClinicalTrials.gov →
Summary
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-08-24; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2023-06-06
Trial Details
NCT Number NCT04528511
Lead Sponsor Shanghai 10th People's Hospital
Collaborators: Shanghai Tong Ren Hospital, Kaifeng Central Hospital, Shanghai 7th People's Hospital, The First Affiliated Hospital of Zhengzhou University, Luoyang Central Hospital
Conditions Atrial Fibrillation New Onset, Acute Myocardial Infarction
Enrollment 774 participants
Start Date 2020-10-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-19